Science and Engineering Ethics 8 (3):429-442 (2002)
Conflicts of interest are common and exist in academia, government, and many industries, including pharmaceutical development. Medical journal editors and others have recently criticized “the pharmaceutical industry,” citing concerns over investigator access to data, approaches to analysis of clinical trial data, and publication practices. Merck & Co., Inc. is a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products, directly and through its joint ventures. Although part of its mission is to provide a superior rate of return to its investors, Merck does not believe this creates an irreconcilable conflict of interest, particularly in activities concerning clinical drug development. We employ rigorous scientific methods to design, conduct, analyze, and report results of clinical trials in the development of innovative drugs and vaccines, with a focus on meeting unmet medical needs and with an ethic that puts the interests of the patient first. This article describes Merck’s approaches to potential conflicts of interest in drug development, particularly with regard to clinical trials. We believe that proprietary interests of the Company can be respected while observing objectivity and transparency in communicating clinical research results. The standards for the review of manuscripts reporting such trials for peer-reviewed publication should be the same, whether they are from Merck or elsewhere.
|Keywords||conflict of interest pharmaceutical drug development publication data access bias investigator clinical research|
|Categories||categorize this paper)|
References found in this work BETA
No references found.
Citations of this work BETA
Conflict of Interest and its Significance in Science and Medicine Warsaw, Poland, 5–6 April, 2002.Wendy Baldwin - 2002 - Science and Engineering Ethics 8 (3):469-475.
Similar books and articles
Conflict or Harmony? Clinical Research and the Medical Press in Russia.Boleslav Lichterman - 2002 - Science and Engineering Ethics 8 (3):383-386.
A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
Climate Change, Nuclear Economics, and Conflicts of Interest.Kristin Shrader-Frechette - 2011 - Science and Engineering Ethics 17 (1):75-107.
Conflict of Interest in Medical Research in Estonia.Arvo Tikk - 2002 - Science and Engineering Ethics 8 (3):317-318.
Managing Financial Conflicts of Interest in Clinical Research.Jordan J. Cohen - 2002 - Science and Engineering Ethics 8 (3):401-406.
Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. [REVIEW]Joel Lexchin - 2012 - Science and Engineering Ethics 18 (2):247-261.
Intrinsic Conflicts of Interest in Clinical Research: A Need for Disclosure.Sharmon Sollitto, Sharona Hoffman, Maxwell J. Mehlman, Robert J. Lederman, Stuart J. Youngner & Michael M. Lederman - 2003 - Kennedy Institute of Ethics Journal 13 (2):83-91.
Stimulating the Development of Drug Treatments to Improve Cognition in Schizophrenia.Micahel F. Green - manuscript
Conflict of Interest as Seen From a Researcher's Perspective.Arrigo Schieppati, Norberto Perico & Giuseppe Remuzzi - 2002 - Science and Engineering Ethics 8 (3):337-342.
Conflicts of Interest in Clinical Practice and Research.Roy G. Spece, David S. Shimm & Allen E. Buchanan (eds.) - 1996 - Oxford University Press.
Added to index2009-01-28
Total downloads33 ( #153,796 of 2,158,177 )
Recent downloads (6 months)1 ( #356,322 of 2,158,177 )
How can I increase my downloads?